These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34504147)

  • 1. Additive quantile mixed effects modelling with application to longitudinal CD4 count data.
    Yirga AA; Melesse SF; Mwambi HG; Ayele DG
    Sci Rep; 2021 Sep; 11(1):17945. PubMed ID: 34504147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of quantile mixed-effects model in modeling CD4 count from HIV-infected patients in KwaZulu-Natal South Africa.
    Yirga AA; Melesse SF; Mwambi HG; Ayele DG
    BMC Infect Dis; 2022 Jan; 22(1):20. PubMed ID: 34983387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Joint modelling of longitudinal and time-to-event data: an illustration using CD4 count and mortality in a cohort of patients initiated on antiretroviral therapy.
    Mchunu NN; Mwambi HG; Reddy T; Yende-Zuma N; Naidoo K
    BMC Infect Dis; 2020 Mar; 20(1):256. PubMed ID: 32228483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Antiretroviral Therapy on CD4+ Cell Count, HIV Viral Load and Death in a South African Cohort: A Modelling Study.
    Shoko C; Chikobvu D; Bessong PO
    Pak J Biol Sci; 2020 Mar; 23(4):542-551. PubMed ID: 32363840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region).
    Seyoum A; Ndlovu P; Temesgen Z
    AIDS Res Ther; 2017 Mar; 14(1):14. PubMed ID: 28302125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling CD4 counts before and after HAART for HIV infected patients in KwaZulu-Natal South Africa.
    Yirga AA; Melesse SF; Mwambi HG; Ayele DG
    Afr Health Sci; 2020 Dec; 20(4):1546-1561. PubMed ID: 34394215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy.
    Shoko C; Chikobvu D
    BMC Infect Dis; 2019 Feb; 19(1):169. PubMed ID: 30770728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis.
    Gezie LD
    BMC Res Notes; 2016 Jul; 9():377. PubMed ID: 27475982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.
    Hoffmann CJ; Schomaker M; Fox MP; Mutevedzi P; Giddy J; Prozesky H; Wood R; Garone DB; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):34-41. PubMed ID: 23344547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.
    Nellen JF; Wit FW; De Wolf F; Jurriaans S; Lange JM; Prins JM
    J Acquir Immune Defic Syndr; 2004 Aug; 36(4):943-50. PubMed ID: 15220701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.
    Tuboi SH; Brinkhof MW; Egger M; Stone RA; Braitstein P; Nash D; Sprinz E; Dabis F; Harrison LH; Schechter M
    J Acquir Immune Defic Syndr; 2007 May; 45(1):52-9. PubMed ID: 17460471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.
    Pantazis N; Touloumi G; Meyer L; Olson A; Costagliola D; Kelleher AD; Lutsar I; Chaix ML; Fisher M; Moreno S; Porter K;
    AIDS; 2016 Mar; 30(6):879-88. PubMed ID: 26636925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa.
    Julg B; Poole D; Ghebremichael M; Castilla C; Altfeld M; Sunpath H; Murphy RA; Walker BD
    PLoS One; 2012; 7(2):e31161. PubMed ID: 22348047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
    Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
    Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.
    De La Mata NL; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Choi JY; Sohn AH; Law MG; Kumarasamy N
    Int J STD AIDS; 2017 Nov; 28(13):1282-1291. PubMed ID: 28632481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.
    Nosyk B; Min J; Lima VD; Yip B; Hogg RS; Montaner JS;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):653-9. PubMed ID: 24135777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.